Canada’s National Advisory Committee on Immunization recommended Monday that the AstraZeneca Covid-19 vaccine shouldn’t be utilized in adults under age 55 while rare cases of great blood clots following vaccination are being investigated, consistent with a release from the committee.
Do Not Administer AstraZeneca To Persons Below 55 Years
The rare cases of great blood clots, referred to as vaccine-induced pro thrombotic immune thrombocytopenia (VIPIT), have recently been reported in Europe following post-licensure use of the AstraZeneca vaccine, primarily in women under the age of 55. According to the vaccine committee, the speed of this adverse event remains to be confirmed and knowledge is being gathered to be more accurate.
“Following population-based analyses of VIPIT assessing the risk of COVID-19 disease by age, and considering that alternate products are available (i.e., mRNA vaccines), from what’s known at this point, there’s substantial uncertainty about the advantage of providing AstraZeneca COVID-19 vaccine to adults under 55 years aged as long as the potential risks related to VIPIT, particularly at the lower estimated rates,” committee officials said. As a precautionary measure, while Health Canada carries out an updated risk versus benefit analysis supported emerging data, the committee is recommending that the vaccine not be offered to adults younger than 55 but will still reassess supported “rapidly evolving evidence.”
Traveling to Canada during Covid-19: What you would like to understand before you go? The committee said because the AstraZeneca vaccine was expected to only structure a little proportion of the Covid-19 vaccines available to be used in Canada, vaccinations “will not be significantly delayed.”CNN reached bent the drugmaker for comment but didn’t get an instantaneous response. AstraZeneca’s development of the vaccine has hit multiple bumps, from the news that two volunteers developed neurological symptoms last fall to a stall within the rollout of the vaccine in several European countries amid fears it’d have caused blood clots. The European Medicines Agency has since said there is no evidence the vaccine can cause blood clots.
Canada’s largest province says it’s within the third wave — and officials worry the vaccine rollout might not happen fast enough The agency’s executive Emer Cooke said several weeks ago the agency had “come to a transparent scientific conclusion that this is often a secure and effective vaccine.”Cooke said the group didn’t find that the vaccine causes clotting, though it couldn’t rule out definitively a link to a rare blood coagulation disorder, of which seven cases are reported out of several million doses given. She said the advantages of using the vaccine outweighed the danger. An agency committee “concluded that the vaccine isn’t related to a rise within the overall risk of thromboembolic events or blood clots,” as Cooke said. More than a dozen European countries had halted their use of the vaccine. Some nations have resumed vaccinations while others have continued their pauses. The World Health Organization has also said there’s no relationship between the vaccine and customary clotting disorders.
Canada received a lift from the Biden administration in recent weeks when the 2 countries struck a deal that will see the US release 1.5 million of its AstraZeneca doses to Canada at some point. The US is stockpiling the AstraZeneca vaccine until it receives FDA authorization, which isn’t likely until around the end of next month. Canada has reported almost 970,000 presumed or confirmed cases of the coronavirus since the beginning of the pandemic and has recorded quite 22,000 deaths.
As the world moves towards vaccination for all to counter the virus, Cooke said Canada needs to take advantage of the US aid and vaccinate all its citizens aged 55 years and above. He also said that only a very small percentage has those side effects.